ストックスクリーナーアプリを入手
15.71
6.73%
0.99
Monte Rosa Therapeutics Inc (GLUE) 最新ニュース
Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Gain Therapeutics (GANX) - The Globe and Mail
Aug Ideas: Can Monte Rosa Therapeutics Inc lead its sector in growthQuarterly Trade Review & Smart Investment Allocation Tips - baoquankhu1.vn
Can Monte Rosa Therapeutics Inc lead its sector in growthTrade Ideas & Long-Term Capital Growth Ideas - baoquankhu1.vn
Breakouts Watch: How sensitive is Monte Rosa Therapeutics Inc to inflationQuarterly Market Review & Growth Focused Stock Reports - baoquankhu1.vn
Big Picture: Does Monte Rosa Therapeutics Inc stock have upside surprise potentialRate Hike & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Monte Rosa J J Supply Deal Refocuses MRT 2359 Prostate Cancer Story - Yahoo Finance
Wall Street Zen Downgrades Monte Rosa Therapeutics to 'Sell' - National Today
Monte Rosa Therapeutics (NASDAQ:GLUE) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Risks Report: Is Monte Rosa Therapeutics Inc forming a bullish divergenceQuarterly Earnings Summary & Verified Technical Signals - baoquankhu1.vn
Does Monte Rosa Therapeutics Inc stock have upside surprise potential - baoquankhu1.vn
NEA group (NASDAQ: GLUE) discloses 9.6% Monte Rosa ownership - Stock Titan
Wells Fargo Sticks to Its Buy Rating for Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Lantheus (LNTH), Perspective Therapeutics (CATX) - The Globe and Mail
Monte Rosa Therapeutics (NASDAQ:GLUE) Announces Earnings Results, Misses Estimates By $0.10 EPS - MarketBeat
Guggenheim Lowers Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target to $30.00 - MarketBeat
Monte Rosa Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Monte Rosa Therapeutics price target lowered to $30 from $34 at Guggenheim - TipRanks
Monte Rosa Therapeutics (GLUE) Quarterly Loss Tests Bullish Profitability Narrative - simplywall.st
Monte Rosa (GLUE) Reports Wider Q4 Loss of $0.55/Share vs $0.34 Estimate, Revenue Misses - AlphaStreet
Analysts Are Bullish on Top Healthcare Stocks: Alto Neuroscience, Inc. (ANRO), Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Monte Rosa Therapeutics Reports Positive Clinical Data and $345M Financing, Advancing Multiple Phase 2 Trials into 2029 - Minichart
Is Monte Rosa Therapeutics Inc stock a hidden gem2026 Earnings Surprises & Advanced Technical Signal Analysis - baoquankhu1.vn
Monte Rosa Therapeutics (GLUE) reports Q4 loss, misses revenue estimates - MSN
Monte Rosa Therapeutics, Inc. (GLUE) Reports Wider Loss Q4 EPS Estimates by 63.4% - AlphaStreet
Monte Rosa’s QuEEN™ Discovery Engine: AI-Driven Molecular Glue Degraders Targeting Undruggable Proteins in Biotechnology 4145465158 - Minichart
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Monte Rosa Therapeutics: Fourth Quarter Financial Results Overview - Bitget
Monte Rosa Therapeutics, Inc. Announces Executive Changes - marketscreener.com
Monte Rosa Therapeutics (GLUE) 2025 Financials: Q4 Loss, Revenue MissNews and Statistics - IndexBox
Monte Rosa Therapeutics touts molecular glue pipeline, tees up GFORCE updates and Phase II plans - MarketBeat
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates - Investing News Network
Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Monte Rosa Therapeutics Swings to Net Loss in Q4, Collaboration Revenue Falls - marketscreener.com
Monte Rosa Therapeutics: Q4 Earnings Snapshot - Barchart.com
Monte Rosa Therapeutics : Corporate Presentation – March 2026 - marketscreener.com
Monte Rosa Therapeutics (NASDAQ: GLUE) touts MGD pipeline and major Novartis, Roche deals - Stock Titan
Monte Rosa Therapeutics Q4 revenue drops, net loss widens on lower milestone payments - TradingView
Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q4 Revenue $2.8M - marketscreener.com
Monte Rosa Therapeutics (GLUE) extends cash runway to 2029 after $345M raise - Stock Titan
Heart risk, prostate cancer: Monte Rosa data and $345M war chest - Stock Titan
Does Monte Rosa (GLUE)–J&J ERLEADA Supply Deal Reframe GLUE’s MYC Degrader Investment Story? - simplywall.st
GLUE SEC FilingsMonte Rosa Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Monte Rosa rises on J&J collaboration for cancer therapy trial (GLUE:NASDAQ) - Seeking Alpha
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer - Bitget
GLUE Stock Price, Quote & Chart | MONTE ROSA THERAPEUTICS INC (NASDAQ:GLUE) - ChartMill
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates - MSN
Monte Rosa Therapeutics (GLUE) Likely to Surpass Earnings Forecasts: Will the Share Price Rise? - Bitget
Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Monte Rosa Therapeutics (GLUE) to Release Quarterly Earnings on Thursday - MarketBeat
Monte Rosa Therapeutics earnings on deck amid revenue decline By Investing.com - Investing.com Australia
Monte Rosa Therapeutics earnings on deck amid revenue decline - Investing.com
Assessing Monte Rosa Therapeutics (GLUE) Valuation After MRT-2359 Data Update And New Public Offering - Yahoo Finance
How Monte Rosa’s MRT-2359 Prostate Cancer Data and Funding Plans Could Shape GLUE’s Risk‑Reward Profile - Yahoo Finance
Is Monte Rosa Therapeutics Inc. stock attractive for income investors2026 Institutional Moves & Daily Growth Stock Tips - Naître et grandir
LifeSci Capital Initiates Coverage of Monte Rosa Therapeutics (GLUE) with Outperform Recommendation - MSN
Profit Review: Will Monte Rosa Therapeutics Inc benefit from AI trendsJuly 2025 Breakouts & High Accuracy Trade Alerts - baoquankhu1.vn
What is Monte Rosa Therapeutics Incs market position2025 Momentum Check & Community Shared Stock Ideas - baoquankhu1.vn
Monte Rosa to focus on prostate cancer only for oncology asset MRT-2359 - MSN
Decliners Report: Is Monte Rosa Therapeutics Inc forming a bullish divergenceIPO Watch & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Dunn Edmund, principal accounting officer, sells Monte Rosa (GLUE) shares for $2496 - Investing.com Canada
1.82%
大文字化:
|
ボリューム (24 時間):